• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Which Menopausal Hormone Therapies Improve Sleep Quality? 

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:  

  • Poor sleep quality is common in recently menopausal women  
  • Cintron et al. (Menopause, 2018) compared the impact of different hormone therapy (HT) formulations on sleep domains 

METHODS:  

  • Data derived from the Kronos Early Estrogen Prevention Study (KEEPS) 
  • KEEPs is a randomized, double-blind, controlled multisite trial that enrolled women 
    • Between 42 and 58 years of age 
    • Between 6 and 36 months since their last menses 
    • Who had serum follicle-stimulating hormone level ≥35 mIU/mL and/or estradiol level <40 pg/mL 
  • Participants completed the Pittsburgh Sleep Quality Index at baseline  
  • Patients randomized 4:4:5 to received   
    • Oral conjugated equine estrogen (o-CEE) 0.45 mg/d plus a placebo (PBO) transdermal patch  
    • Transdermal 17β-estradiol (t-E2) 50 μg/d plus a PBO pill  
    • PBO pills and patch   
  • Active treatment groups received 200 mg cyclic progesterone and PBO group received a PBO capsule for the first 12 days of each month  
  • Intervention occurred at 6, 18, 36, and 48 months  
  • Global Pittsburgh Sleep Quality Index (PSQI) scores (0 to 21 points) and individual sleep domain scores (0 to 3 points) were compared and correlated with vasomotor symptom (VSM) scores based on hot flashes and night sweats  
  • Poor sleep quality was defined by a PSQI global score >8 

RESULTS:  

  • Global PSQI scores were similar across groups at baseline 
  • Compared with baseline values, both HT groups and the PBO group showed a reduction in average PSQI global scores over 4 years of treatment (each P < 0.001) 
  • PSQI scores were improved in both HT formulations when compared to PBO  
    • O-CEE: Average PSQI change −1.27 (P=0.001 compared to PBO)  
    • T-E2: Average PSQI change −1.32 (P=0.002 compared to PBO)  
  • With HT use, domain scores for sleep satisfaction and latency improved 
  • The domain score for sleep disturbances improved more with t-E2 than o-CEE or PBO  
  • Global sleep scores were significantly correlated with vasomotor symptom severity 
    • Hot flashes: rs = 0.170, P < 0.001  
    • Night sweats: rs = 0.177, P < 0.001  
  • Change in scores for all domains except sleep latency and sleep efficiency correlated with change in severity of VMS 
  • Multivariable analysis demonstrated that improvement in VMS does not fully account for the improved sleep outcomes among women in the HT group 
    • Improved sleep mediated through VMS relief in those with moderate/severe symptoms but not those with none to mild symptoms 

CONCLUSION:  

  • Sleep quality improved with both HT formulations (transdermal slightly better than oral)  
  • Sleep disturbance improved more with transdermal patch which may reflect more consistent hormonal levels (e.g. if oral medication was taken in the morning)  
  • Sleep duration was not affected by HT, indicating that other life factors may be involved 

Learn More – Primary Sources:  

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) 

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
Insomnia in Menopause: How do Treatments Compare?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site